Business Context and Reporting Period
This Form 8-K Current Report was filed by Impact BioMedical Inc. on October 3, 2024. The filing primarily addresses Item 5.02 regarding the execution of a new Executive Employment Agreement with Frank D. Heuszel, the Company's Chief Executive Officer, Chairman, and President.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On October 3, 2024, the Company entered into a three-year Executive Employment Agreement with Frank D. Heuszel. The key terms include:
- Employment Term: October 3, 2024, to October 3, 2027.
- Base Salary: $200,000 for Year 1; $250,000 for Year 2; $250,000 for Year 3.
- Mandatory Bonus: $150,000 for Year 1; $100,000 for Year 2; $100,000 for Year 3 (contingent on continuous employment through the anniversary of the award date).
- Discretionary Bonus: Eligible for bonuses authorized by the Board of Directors at their sole discretion.
- Equity Grant: Option to purchase 300,000 shares of common stock under the 2023 Plan at an exercise price of $3.00 per share (fair market value on grant date).
- Termination: The Company may terminate for "Cause" without notice; the Executive may terminate for "Good Reason."
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies related to financial performance are disclosed in this report, other than the standard contractual terms regarding termination.
Investor Verification Checklist
- Verify the total potential cash compensation ($350,000 in Year 1; $350,000 in Years 2 and 3) relative to the Company's current cash position.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the dilution impact of the 300,000 share option grant on existing shareholders.
- Check the Company's most recent 10-K or 10-Q for current liquidity status to assess the ability to fund the mandatory bonuses.